Key Insights

Highlights

Treatment Research

1 treatments under study, led by Trastuzumab Emtansine

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06595563Phase 2Terminated

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

Showing all 1 trials

Research Network

Common Treatments

  • Trastuzumab Emtansine1

Active Sponsors

  • Jules Bordet Institute1
  • Roche1
  • Institut Jules Bordet1

Top Investigators

Related Conditions

  • Her2positive Advanced Breast Cancer1
  • Her2positive Metastatic Breast Cancer1

Activity Timeline